Moleculin Biotech Secures Two New U.S. Patents

An update from Moleculin Biotech ( (MBRX) ) is now available.

On May 5, 2025, Moleculin Biotech announced the granting of two additional U.S. patents for Annamycin, enhancing its intellectual property portfolio. These patents, extending until June 2040, cover methods of making liposomal Annamycin and its suspension, bolstering the company’s efforts in developing Annamycin as a novel treatment for AML and other cancers. The company continues to advance its Phase 3 MIRACLE trial and holds Fast Track and Orphan Drug Designations from the FDA and EMA, indicating significant progress in its development pathway.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is a next-generation anthracycline designed to avoid cardiotoxicity and multidrug resistance, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.

YTD Price Performance: -41.81%

Average Trading Volume: 5,888,117

Technical Sentiment Signal: Buy

Current Market Cap: $14.55M

See more data about MBRX stock on TipRanks’ Stock Analysis page.